ReviewAdvances in medical education and practice2018
Evolving role of pharmaceutical physicians in medical evidence and education.
Review in Advances in medical education and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Visionary Health Architects and Leaders: The Strategic Role of Medical Advisors in Modern Pharma.Pharmaceutical medicine · 2025Review
- Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities.Pharmaceutical medicine · 2024Review
- Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs.Pharmaceutical medicine · 2024Article
- Redefining the Role of Medical Affairs Professionals as Innovators and Leaders in Industry-Led Medical Education.Pharmaceutical medicine · 2024Article
- Journey from an Enabler to a Strategic Leader: Integration of the Medical Affairs Function in ESG Initiatives and Values.Pharmaceutical medicine · 2023Article
- Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core.Pharmaceutical medicine · 2022Article
- Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond.Pharmaceutical medicine · 2022Review
- Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.Pharmaceutical medicine · 2022Article
- Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians.Frontiers in pharmacology · 2022Article
- Marketing training strategies that pharmaceutical sales managers use to reduce unethical behavior.Journal of education and health promotion · 2022Article
- Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry.F1000Research · 2022Article
- Promoting Best Practices for Medical Science Liaisons Position Statement from the APPA, IFAPP, MAPS and MSLS.Therapeutic innovation & regulatory science · 2021Review
- Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers.Pharmaceutical medicine · 2020Article
- Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries.Journal of multidisciplinary healthcare · 2020Review
- Massive open online courses (MOOCs) for continuing medical education - why and how?Advances in medical education and practice · 2019Article
- Past, Present, and Likely Future of Nutraceuticals in India: Evolving Role of Pharmaceutical Physicians.Journal of pharmacy & bioallied sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of pharmaceutical physicians who are the experts working in pharmaceutical companies has progressed over the last few decades, from supervising research and development (R&D) studies and/or providing support to marketing teams to serving an independent critical function. In this review, we focus on pharmaceutical physicians serving medical affairs functions in the pharmaceutical industry. Historically, members of the medical affairs team mainly provided a bridge between commercial teams and the R&D sector and between the organization and external stakeholders. Such teams may even have been managed by other departments, with an emphasis on acquiring and generating data for regulatory purposes. In recent years, the role of medical affairs has broadened due to a change in focus and the increasingly stringent regulatory landscape. Strict regulations require the detachment of commercial from medical activities within pharmaceutical organizations. This change provides an opportunity for a different type of partnership, allowing scientifically minded and medically driven initiatives. This article summarizes the key role of pharmaceutical industry-based physicians in medical affairs and discusses the emerging and evolving role of medical affairs for value creation in evidence generation and medical education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.